Trials / Completed
CompletedNCT01914159
Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- University Hospital, Bonn · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The Ranibizumab in Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration (RIP) Study is a prospective, multicenter, uncontrolled, interventional phase 2 clinical trial that investigates the effect of fixed monthly intravitreal injections of ranibizumab (Lucentis, Novartis Pharma, Germany) on visual acuity and retinal morphology over a study period of 12 months in 30 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany) | Monthly intravitreal injections |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2016-03-01
- Completion
- 2016-03-01
- First posted
- 2013-08-01
- Last updated
- 2019-08-15
- Results posted
- 2019-08-15
Locations
3 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01914159. Inclusion in this directory is not an endorsement.